31
Views
9
CrossRef citations to date
0
Altmetric
Original Articles

Assessment of diabetic macrovascular complications: a prediabetes model

, , , , &
Pages 59-66 | Accepted 04 Nov 2009, Published online: 23 May 2016

  • Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075–81.
  • Yan S, Ramasamy R, Naka Y, Schmidt A. Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159–69.
  • Caboral M, Mitchell J. New guidelines for heart failure focus on prevention. Nurse Pract 2003; 28: 13, 16, 22–3.
  • Bell DSH. Chronic complications of diabetes. South Med J 2002; 95: 30–4.
  • Vijan S, Stevens DL, Herman WH, Funnell MM, Standiford CJ. Screening, prevention, counselling and treatment for the complications of type II diabetes mellitus: putting evidence into practice. J Gen Intern Med 1997; 12: 567–80.
  • Shaw JE, Chisholm DJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003; 179: 379-83.
  • Tirosh A, Shai I, Tekes-Manova D et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454–62.
  • Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472–9.
  • Festa A, Williams K, Hanley AJG et al. Pre-diabetes associated with lipid abnormalities. Circulation 2005; 111: 3465–72.
  • Banerjee M, Cruickshank JK. Prediabetes: is the term useful? Br J Diabetes Vasc Dis 2004; 4: 221–5.
  • Williams DE, Cadwell BL, Cheng YJ et al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999–2000. Pediatrics 2005; 116: 1122–6.
  • Beaser RS, Blonde L, Weissman PN. Metabolic syndrome and cardiovascular risk: treating the clinical spectrum. Medscape 2005 (http://cme.medscape.com/viewprogram/4685) (Accessed 15 August 2009).
  • Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association and the American Heart Association. Circulation 2004; 109: 3244–55.
  • Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 65–71.
  • Michos ED, Nasir K, Braunstein JB et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006; 84: 201–6.
  • Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6–19.
  • Smith DA. Atherosclerotic cardiovascular disease: emerging laboratory risk factors. Clin Lab Med 2006; 26: ix–xi.
  • New Zealand Guidelines Group 2005. The assessment and management of cardiovascular risk. Handbook for Primary Care Practitioners. (www.nzgg.org.nz/guidelines/0101/050624_CVD_Resource_(Final)_v5_for_printing_2.pdf) (Accessed 15th August 2009).
  • Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615–25.
  • Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med 2004; 13: 715–9.
  • Kacmaz M, Ozturk HS, Cete S, Kavutcu M, Durak I. The effects of smoking on antioxidant defence system and membrane free fatty acid content of erythrocytes and plasma lipid parameters: protective role of antioxidant vitamins. Nutr Res 1997; 17: 931–40.
  • American Diabetes Association. Pre-diabetes. (www.diabetes.org/diabetes-prevention/pre-diabetes.jsp). (Accessed 15 August 2009).
  • American Diabetes Association. Frequently asked questions about pre-diabetes. (www.diabetes.org/pre-diabetes/faq.jsp). (Accessed 15 August 2009).
  • Nwose EU, Jelinek HF, Richards RS, Kerr PG. Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications Br J Biomed Sci 2007; 64: 35–43.
  • Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type I diabetes in children and adolescents. Diabetes Care 1998; 21: 1736–42.
  • Goldfarb AH, Bloomer RJ, McKenzie MJ. Combined antioxidant treatment effects on blood oxidative stress after eccentric exercise. Med Sci Sports Exerc 2005; 37: 234–9.
  • Manuel y Keenoy B, Vertommen J, De Leeuw I. Divergent effects of different oxidants on glutathione homeostasis and protein damage in erythrocytes from diabetic patients: effects of high glucose. Mol Cell Biochem 2001; 225: 59–73.
  • Memisogullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct 2003; 21: 291–6.
  • Tsimikas S. Measures of oxidative stress. In: Smith DA ed. Atherosclerotic cardiovascular disease: emerging laboratory risk factors. Clin Lab Med 2006; 26: 571–90.
  • Malone PC, Agutter PS. The aetiology of deep venous thrombosis. QJM 2006; 99: 581–93.
  • Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143: 180–90.
  • Nwose EU, Richards RS, Kerr PG, Tinley P, Jelinek HF. Atherothrombosis and oxidative stress: the connection and correlation in diabetes. Redox Rep 2009; 14: 55–60.
  • Nwose EU, Richards RS, Kerr RG, Tinley R, Jelinek H. Oxidative damage indices for the assessment of subclinical diabetic macrovascular complications. Br J Biomed Sci 2008; 65: 136–41.
  • Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007; 186: 461–5.
  • Linder R, Konig IR, Weimar C, Diener HC, Poppl SJ, Ziegler A. Two models for outcome prediction: a comparison of logistic regression and neural networks. Methods Inf Med 2006; 45: 536–40.
  • Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381–478.
  • Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27: 2178–83.
  • Smith GD, Timpson N, Lawlor DA. C-reactive protein and cardiovascular disease risk: still an unknown quantity? Ann Intern Med 2006; 145: 70–2.
  • Kemp TM, Barr EL, Zimmet PZ et al. Glucose, lipid and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab. Diabetes Care 2005; 28: 1490–2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.